ClinicalTrials.gg
Not yet recruitingNCT06897917Updated Mar 27, 2025

Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain

A Phase 4 interventional study of Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-release Tablets in Opioid-Induced Constipation and Pain Cancer, sponsored by Henan Cancer Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-27.

Sponsored by Henan Cancer Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
203
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is a prospective, single-arm, multicenter, real-world study to evaluate effect of bowel function, analgesic effect, quality of life, and safety of Mimeixin® in Chinese patients with severe cancer pain.

Read the detailed description

Cancer remains a significant health concern globally, with rising incidence and mortality rates. In 2022, there were 19.96 million new cancer cases and 9.74 million cancer deaths worldwide, including 4.8 million new cases and 2.6 million deaths in China. Cancer patients often experience pain during treatment, with 40% of patients reporting persistent pain, particularly moderate to severe pain, occurring in 40%-80% of cases. Unrelieved pain can exacerbate symptoms such as anxiety, depression, fatigue, insomnia, and loss of appetite, significantly impacting patients' quality of life. Opioids, represented by morphine and oxycodone, are widely used for the treatment of moderate to severe cancer pain.

Long-term opioid use often leads to gastrointestinal adverse events, with opioid-induced constipation (OIC) being the most common, significantly affecting patients' quality of life and treatment compliance. Although some guidelines recommend laxatives as prophylactic and first-line treatment for OIC, approximately half of the patients do not experience adequate symptom improvement. The mechanism of OIC primarily involves the activation of intestinal μ-opioid receptors, which is difficult to address solely with laxatives. The key to treating OIC lies in blocking the stimulation of μ-opioid receptors in the gastrointestinal tract while maintaining the analgesic effect of opioid receptors in the central nervous system.

Oxycodone/naloxone sustained-release tablets, a combination of the opioid receptor agonist oxycodone and the antagonist naloxone, effectively provide analgesia while improving OIC. Foreign studies have demonstrated that this medication significantly improves OIC while maintaining good analgesic effects, with good long-term tolerability. Mimeixin® is an oxycodone/naloxone sustained-release tablet developed with reference to the foreign-listed drug Targin®. It was approved by the National Medical Products Administration of China in June 2024 for the treatment of severe pain in adults that requires opioid analgesics for adequate control. However, clinical validation has not been conducted among Chinese cancer pain patients. Therefore, a prospective, single-arm, multicenter, real-world study is planned to evaluate the effect in bowel function, analgesic effect, quality of life, and safety of Mimeixin® in Chinese patients with severe cancer pain in real-world clinical practice.

02

Conditions studied

  • Opioid-Induced Constipation
  • Pain Cancer

Keywords

  • opioid-induced constipation
  • severe cancer pain
  • Oxycodone/naloxone sustained-release tablets
03

In context

Opioid-Induced Constipation

87 studies on the registry are indexed under Opioid-Induced Constipation; 6 are open to participants now.

This study's planned enrollment of 203 is above the median of 119 across 68 interventional studies indexed under Opioid-Induced Constipation.

Browse Opioid-Induced Constipation studies →

Lead sponsor

Henan Cancer Hospital is the lead sponsor of 235 studies on the registry; 131 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old, with a histological or pathological diagnosis of advanced cancer.
  • Be diagnosed with severe (NRS ≥ 7 points) cancer pain, requiring regular opioid therapy.
  • Diagnosed with OIC according to the Rome IV diagnostic criteria for OIC, with a BFI score ≥ 30.
  • Determined by the investigator to be eligible for treatment with oxycodone/naloxone sustained-release tablets.
  • Estimated survival period of more than 3 months.
  • Voluntarily sign an form.

Exclusion criteria

Exclusion Criteria:

  • Patients with to oxycodone/naloxone sustained-release tablets (including allergy to the active ingredients or any of this product; severe respiratory depression accompanied by hypoxemia and/or hypercapnia; severe ; pulmonary heart disease; severe bronchial asthma; paralytic ileus caused by non-opioid drugs; moderate to severe liver function impairment).
  • Patients with structural malformations of the gastrointestinal tract (such as intestinal obstruction, stenosis), other known gastrointestinal diseases/symptoms (including cancer to the digestive tract), or gastrointestinal digestion and absorption disorders.
  • Patients with language communication barriers, cognitive impairments or mental illnesses, intracranial metastasis of tumors with consciousness disorders, or consciousness disorders caused by other reasons.
  • Other situations that the investigator judges as unsuitable for inclusion in the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
203 participants (estimated)

Study arms

  • Experimental
    Oxycodone/naloxone sustained-release tablets treatment group

    Patients receiving oxycodone naloxone sustained-release tablets were included in the study cohort.

    Drug: Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-release Tablets

Interventions

  • DrugOxycodone Hydrochloride and Naloxone Hydrochloride Sustained-release Tablets

    1. Calculate the total opioid dosage administered to the patient in the previous 24 hours and convert it to an equivalent dose of oxycodone/naloxone sustained-release tablets(Mimeixin). 2. Based on the principle of incremental dosing, calculate the total dosage to be administered on the day of enrollment, divide it into two portions, and administer one portion every 12 hours (q12h). 3. In case of breakthrough pain during treatment, administer an equivalent dose of immediate-release morphine or other medications equivalent to 10%-20% of the 24-hour background dosing for relief. 4. If the number of breakthrough pain events exceeds 2 in a day after dosing, adjust the dosage again based on the incremental dosing principle. Adjustments should be made every 1-2 days, with each adjustment increasing the dose by a gradient of 5 mg/2.5 mg or 10 mg/5 mg of oxycodone/naloxone sustained-release tablets, twice daily, and so on. The maximum daily dose of oxycodone should not exceed 160 mg.

    Also known as: Mimeixin

06

What researchers measure

Primary outcomes

  1. Changes of Patients' Bowel Function of day 28

    The BFI score was used for evaluation, and the data were repeatedly measured. A one-way repeated measures ANOVA model was used, which included follow-up time and baseline BFI values; the variation curve of BFI with follow-up time was also plotted. The analytical method for repeatedly measured data of secondary endpoints was consistent with the primary analytical method.

    Time frame: pre-intervention, day 7, day 14, day 21 and day 28 after the intervention

Secondary outcomes

  1. Changes of Cancer Pain with NRS

    Assess and record pain experienced within 24 hours using the Numerical Rating Scale (NRS) The numerical rating scale (NRS) uses 0-10 to represent different levels of pain, with higher scores indicating higher levels of pain.

    Time frame: through study completion, an average of 4 weeks

  2. Changes of Cancer Pain with BPI-SF

    Assess and record pain experienced concurrently with the Brief Pain Inventory-Short Form (BPI-SF). The Brief Pain Inventory-Short Form (BPI-SF) was used to assess the degree of pain effect in the past 24 hours on a scale of 0-10, with 0 as no effect and 10 as complete effect.

    Time frame: through study completion, an average of 4 weeks

  3. Changes of breakthrough pain

    Documented the frequency of breakthrough pain within 24 hours, as well as the types and amounts of rescue medications used within 24 hours.

    Time frame: within 24 hours

  4. Frequency of bowel movements and CSBMs

    Documented the number of bowel movements and CSBMs.CSBM is defined as a spontaneous bowel movement accompanied by a complete sense of emptying, without the use of rescue laxatives or manual assistance.

    Time frame: through study completion, an average of 4 weeks

  5. Laxative Use

    Record the type and amount of laxatives used.

    Time frame: through study completion, an average of 4 weeks

  6. Assessment of withdrawal symptoms

    Recorded using Subjective Opioid Withdrawal Scale (SOWS).

    Time frame: pre-intervention, day 2 and day 28 after the intervention

  7. Changes of Quality of Life with EQ-5D-5L

    The EQ-5D-5L consists of two main components: the EQ-5D Descriptive System and the EQ-5D Visual Analogue Scale (VAS). A score of 1-5 and a score of 0-100 were used to describe health status, with higher EQ-5D Descriptive System scores indicating worse health status and higher EQ-5D VAS scores indicating better health status.

    Time frame: day 7, day 14, day 21 and day 28 after the intervention

  8. Changes of Quality of Life with SF-6D

    The SF-6D describes health status on a scale of 0-5. The best health status was "111111", and the worst health status was "555655".

    Time frame: day 7, day 14, day 21 and day 28 after the intervention

  9. Changes of Quality of Life with PAC-QOL

    The PAC-QOL assesses the impact of constipation on your daily life over the past 2 weeks. It consists of 28 questions, each scored from 0 to 4.

    Time frame: day 7, day 14, day 21 and day 28 after the intervention

  10. Incidence of adverse events (Safety Evaluation)

    The grading criteria for adverse events follow the Common Terminology Criteria for Adverse Events 5.0 (CTCAE 5.0) of the National Cancer Institute (NCI).

    Time frame: through study completion, an average of 4 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2025; primary completion for Dec 2025, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2025
First posted
Mar 27, 2025
StartEst.
Apr 2025
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Mar 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06897917
Responsible party
Sponsor
First posted
Mar 27, 2025
Start date
Apr 2025 (estimated)
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Mar 27, 2025

Study contacts

Suxia Luo, Doctor
Contact
luosxrm@163.com
8618638553211
Suxia Luo, Doctor
principal investigator · Henan Cancer Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion